Generics - Ranbaxy Laboratories, Markets & Marketing

Filter

Popular Filters

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Indian pharmaceuticals market led by Ranbaxy in terms of revenue

31-01-2013

The Indian pharmaceutical market is the world's third-largest in terms of volume and stands 14th in terms…

Asia-PacificBioconBiotechnologyGenericsMarkets & MarketingPanacea BiotecPharmaceuticalRanbaxy LaboratoriesSerum Institute of India

Daiichi Sankyo and Ranbaxy combine business operations in Thailand

16-01-2013

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its 64%-owned affiliate Ranbaxy Laboratories (AB:…

Asia-PacificDaiichi SankyoGenericsManagementMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Ranbaxy debuts authorized Actos generic in USA, followed by Teva and Mylan

20-08-2012

The US subsidiary of Ranbaxy Laboratories (AB: BO), India's largest drugmaker, has launched authorized…

ActoplusMetActosDiabetesGenericsMarkets & MarketingMylan LaboratoriesNorth AmericaRanbaxy LaboratoriesRegulationTakeda PharmaceuticalsTeva Pharmaceutical Industries

Daiichi Sankyo and Ranbaxy debut hybrid business model in Venezuela

20-06-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) announced that its Daiichi Sankyo Venezuela unit would…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Daiichi Sankyo and Ranbaxy launch Sevikar in Romania

19-04-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned Indian subsidiary Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSevikar

Ranbaxy opens new plant in Morocco

12-03-2012

Ranbaxy Morocco, a unit of India's largest drugmaker Ranbaxy Laboratories (AB: BO), which is majority…

Daiichi SankyoGenericsMarkets & MarketingRanbaxy LaboratoriesRest of the World

Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry

07-03-2012

The German subsidiary of India's Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday…

atorvastatinBasics GmbHCardio-vascularDaiichi SankyoEuropeGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

Ring in generics in 2012 and beyond, says Zacks Equity Research

03-01-2012

The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals (Nasdaq:…

Dr Reddy's LaboratoriesGenericsMarkets & MarketingNorth AmericaPatentsRanbaxy LaboratoriesSandozTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy

06-12-2011

Reimbursement Intelligence, a USA-based market-research firm, has announced how payers predict the impact…

CaduetCardio-vascularGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

US launch of generic Lipitor confirms value of competition, says GPhA

01-12-2011

Commenting on this week’s US roll out for generic copies of Pfizer blockbuster cholesterol lowerer…

GenericsLipitorMarkets & MarketingNorth AmericaPatentsPfizerRanbaxy LaboratoriesWatson Pharmaceuticals

Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA

01-12-2011

US generic drug major Watson Pharmaceuticals (NYSE: WPI) was the first to confirm yesterday that it has…

atorvastatinCardio-vascularGenericsLipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRanbaxy LaboratoriesTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Daiichi Sankyo extends reach in Italy, with Ranbaxy to market its products

05-10-2011

The Italian subsidiaries of Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned India-based…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingRanbaxy Laboratories

Ranbaxy debuts first approved generic of Nexium in the UK

05-09-2011

The UK subsidiary of India largest drugmaker Ranbaxy (RANB: BO) says that it has successfully launched…

AstraZenecaEuropeGastro-intestinalsGenericsMarkets & MarketingNexiumRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy expand business in Mexico with launch of olmesartan

02-08-2011

Japanese drug major Daiichi Sankyo (TYO: 4568) and its 64% owned Indian affiliate Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoGenericsMarkets & MarketingolmesartanRanbaxy LaboratoriesSouth America

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top